ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
NCT02431403
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
94
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG:
ESHAP-Imatinib
Sponsor
Pusan National University Hospital